FindTrial
Sign In

Effects of KRAS/NRAS/BRAF Mutations on the Clinicopathological Features of TP53-Mutant Colorectal Cancer

Effects of KRAS/NRAS/BRAF Mutations on the Clinicopathological Features of TP53-Mutant Colorectal Cancer

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600127263
Enrollment
Unknown
Registered
2026-06-28
Start date
2026-06-28
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colorectal cancer

Interventions

Observation Group (TP53-mutated Colorectal cancer):None
Control group (non-TP53 mutant colorectal cancer):None

Sponsors

The First Affiliated Hospital of Dalian Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 100 Years

Inclusion criteria

Inclusion criteria: 1.Patients aged 18 or above who have been diagnosed with colorectal cancer and are undergoing surgical treatment; 2. Patients who undergo genetic testing after surgery;

Exclusion criteria

Exclusion criteria: 1. Those with incomplete clinicopathological data; 2. Those with severe cardiac or pulmonary dysfunction;

Design outcomes

Primary

MeasureTime frame
Pathological staging of colorectal cancer after surgery;—

Secondary

MeasureTime frame
General patient information and clinical data;The status of related genes( KRAS/NRAS/BRAF/TP53);—

Countries

China

Contacts

Public ContactZhang Shoujia

The First Affiliated Hospital of Dalian Medical University

shoujiazhang163@163.com+86 411 83635963

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Jul 3, 2026